• 제목/요약/키워드: novel enzyme

검색결과 614건 처리시간 0.05초

FAH gene novel mutation을 가진 만성형 Hereditary tyrosinemia 1형 (Chronic Hereditary Tyrosinemia Type I with Novel Mutation in FAH Gene)

  • 양성민;최효원;강윤구;이진성;남궁미경
    • 대한유전성대사질환학회지
    • /
    • 제20권2호
    • /
    • pp.55-62
    • /
    • 2020
  • HT-1은 FAH의 돌연변이에 의한 FAH의 결함으로 타이로신 대사의 중간산물인 FAA, SA가 간세포, 신세뇨관 세포에 축적되어 증상을 일으키는 대사이상 질환의 일종이다. 생후 6개월 내에 증상이 발현되는 급성형의 경우 간기능 저하에 따른 간부전, 응고장애, Fanconi 증후군, FAA 축적에 의한 델타-아미노레부릭산 탈수효소의 기능 저하에 의한 포르피린증 유사 증상이 발생한다. 증상이 생후 12개월 이후 발현되는 만성형의 경우 간경화, 간세포암종, 저인산혈증 구루병, 인지기능 저하와 같은 증상이 발생할 수 있다. 본 증례는 생후 20개월 경 간비장비대, 내반슬, 대상산증으로 대사이상질환 감별을 위하여 시행한 탠덤매스 분석에서 특이 소견이 보고되지 않았으나, 57개월에 시행한 복부 초음파 검사에서 간경화, 소변 유기산 분석에서 SA 상승, NGS에서 FAH 돌연변이 c.107T>C (p.Ile 36Thr), c.614T>C (pPhe205Ser)가 확인되어 HT-1이 진단된 증례로, 환아는 현재까지 NTBC 및 단백제한식이를 유지하며 특이 합병증 없이 외래 추적관찰 중이다. HT-1은 혈장 타이로신 농도가 증가하지 않는 경우도 있으며, 만성형의 경우 임상양상이 생후 12개월 이후에 나타나므로 탠덤매스 검사에서 음성 소견이 보고되어도 임상적으로 의심되는 경우 소변 유기산 분석과 같은 추가적 검사가 필요하다. 또한 기존의 탠덤매스 분석을 통하여는 HT-1이 진단되지 않는 경우가 있을 수 있어, 신생아 선별검사에서 혈장 타이로신 농도뿐 아니라 SA 농도도 추가로 확인하는 것의 비용 편익에 대한 추가적 연구가 필요하다.

인체 SIP 단백질에 특이적인 단일클론 항체의 특성 (Characterization of a Monoclonal Antibody Specific to Human Siah-1 Interacting Protein)

  • 윤선영;주종혁;김주헌;강호범;김진숙;이영희;권두한;김창남;최인성;김재화
    • IMMUNE NETWORK
    • /
    • 제4권1호
    • /
    • pp.23-30
    • /
    • 2004
  • Background: A human orthologue of mouse S100A6-binding protein (CacyBP), Siah-1-interacting protein (SIP) had been shown to be a component of novel ubiquitinylation pathway regulating $\beta$-catenin degradation. The role of the protein seems to be important in cell proliferation and cancer evolution but the expression pattern of SIP in actively dividing cancer tissues has not been known. For the elucidation of the role of SIP protein in carcinogenesis, it is essential to produce monoclonal antibodies specific to the protein. Methods: cDNA sequence coding for ORF region of human SIP gene was amplified and cloned into an expression vector to produce His-tag fusion protein. Recombinant SIP protein and monoclonal antibody to the protein were produced. The N-terminal specificity of anti-SIP monoclonal antibody was conformed by immunoblot analysis and enzyme linked immunosorbent assay (ELISA). To study the relation between SIP and colon carcinogenesis, the presence of SIP protein in colon carcinoma tissues was visualized by immunostaining using the monoclonal antibody produced in this study. Results: His-tag-SIP (NSIP) recombinant protein was produced and purified. A monoclonal antibody (Korea patent pending; #2003-45296) to the protein was produced and employed to analyze the expression pattern of SIP in colon carcinoma tissues. Conclusion: The data suggested that anti-SIP monoclonal antibody produced here was valuable for the diagnosis of colon carcinoma and elucidation of the mechanism of colon carcinogenesis.

Phage Display 기법을 이용한 B형 간염 바이러스 Polymerase의 RNase H 활성을 억제하는 인간 단세포군 항체의 개발 (Development of Human Antibody Inhibiting RNase H Activity of Polymerase of Hepatitis B Virus Using Phage Display Technique)

  • 이성락;송은경;정영주;이영이;김익중;최인학;박세광
    • IMMUNE NETWORK
    • /
    • 제4권1호
    • /
    • pp.16-22
    • /
    • 2004
  • Background: To develop a novel treatment strategy for hepatitis B virus infection, a major cause of liver chirosis and cancer, we aimed to make human monoclonal antibodies inhibiting RNase H activity of P protein playing in important role in HBV replication. In this regard, phage display technology was employed and demonstrated as an efficient cloning method for human monoclonal antibody. So this study analysed the usability of human monoclonal antibody as protein based gene therapy. Methods: RNase H of HBV was expressed as fusion protein with maltose binding protein and purified with amylose resin column. Single chain Fv (scFv) phage antibody library was constructed by PCR cloning using total RNAs of PBMC from 50 healthy volunteers. Binders to RNase H were selected with BIAcore 2000 from the constructed library, and purified as soluble antibody fragment. The affinity and sequences of selected antibody fragments were analyzed with BIAcore and ABI automatic sequencer, respectively. And finally RNase H activity inhibiting assay was carried out. Results: Recombinant RNase H expressed in E. coli exhibited an proper enzyme activity. Naive library of $4.46{\times}10^9cfu$ was screened by BIAcore 2000. Two clones, RN41 and RN56, showed affinity of $4.5{\times}10^{-7}M$ and $1.9{\times}10^{-7}M$, respectively. But RNase H inhibiting activity of RN41 was higher than that of RN56. Conclusion: We cloned human monoclonal antibodies inhibiting RNase H activity of P protein of HBV. These antibodies can be expected to be a good candidate for protein-based antiviral therapy by preventing a replication of HBV if they can be expressed intracellularly in HBV-infected hepatocytes.

한국인 당원병 제 Ia형 환자의 돌연변이 분석 (Mutation Analysis of Korean Patients with Glycogen Storage Disease Type Ia)

  • 김종원;박지연;서정기
    • Pediatric Gastroenterology, Hepatology & Nutrition
    • /
    • 제4권2호
    • /
    • pp.213-217
    • /
    • 2001
  • 목적: 당원병 Ia형(von Gierke disease)은 glucose 6-phosphatase (G6Pase)의 결함으로 인하여 출생 시부터 복부팽만과 간종대가 나타나고 저혈당, 락트 산혈증(lactic acidemia), 고지방혈증(hyperlipidemia), 고뇨산혈증(hyperuricemia) 등을 초래하며 점차 성장발육부전이 진행되는 상염색체 열성 유전성 질환이다. 본 연구에서는 한국인 GSD Ia 환자 9명을 대상으로 G6Pase 유전자의 돌연변이형에 관한 분석을 처음으로 시행하고자 하였다. 방법: 임상적인 증상과 G6Pase 효소 측정결과를 통하여 GSD Ia로 진단된 9명 환자의 혈액에서 genomic DNA를 분리하여 G6Pase 유전자의 5개 exon 부분이 포함되도록 polymerase chain reaction(PCR) 한 후 PCR 산물을 direct sequencing 하였다. 결과: 9명의 GSD Ia 환자 중 7명 환자에서 g727t homozygote 돌연변이를 발견하였고, 한 환자는 heterozygote로서 g727t 돌연변이와 c611g 돌연변이가 발견되었다. 나머지 한 명에서는 g727t 돌연변이 하나만 발견할 수 있었다. 한 개의 allele에서 발견된 c611g 돌연변이는 exon 4의 178번 아미노산 proline이 alanine으로 변경되는 것으로 지금까지 보고된 바 없는 새로운 돌연변이이다. 결론: 현재까지는 GSD Ia병의 정확한 진단을 위해서 환자의 간 생검 조직에서 G6Pase 효소의 활성도를 측정하는 것이 필요하였으나 한국인 GSD Ia 환자의 경우 g727t 돌연변이가 대부분을 차지하고 있기 때문에 앞으로는 상당수의 환자에서 혈액 채취만으로도 G6Pase 유전자 분석을 통한 GSD 진단이 손쉽게 이루어질 수 있으리라고 생각된다.

  • PDF

류마티스관절염 환자의 활액 세포에서 IL-17과 $IL-1{\beta}$에 의한 IL-23p19의 발현 증가 (IL-23 P19 Expression Induced by IL-17 and $IL-1{\beta}$ in Rheumatoid Arthritis Synovial Mononuclear Cells)

  • 조미라;허유정;오혜좌;강창민;이선영;홍연식;김호연
    • IMMUNE NETWORK
    • /
    • 제8권1호
    • /
    • pp.29-37
    • /
    • 2008
  • Interleukin-23 (IL-23) is a novel pro-inflammatory cytokine which has been implicated to play a pathogenic role in rheumatoid arthritis (RA). This study was undertaken to investigate the IL-23 inductive activity of the proinflammatory cytokine IL-17, $IL-1{\beta}$ and tumor necrosis factor (TNF-${\alpha}$) in RA synovial fluid mononuclear cells (SFMC). Expression of IL-23p19, IL-17, $IL-1{\beta}$ and TNF-${\alpha}$ in joint was examined by immunohistochemistry (IHC) of patients with RA and osteoarthritis (OA). The effects of IL-17 and $IL-1{\beta}$ on expression of IL-23p19 in human SFMC from RA patients were determined by reverse transcriptase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA). IL-23p19 was expressed in the RA fibroblast like synoviocyte (FLS), but not from OA FLS. Similar to the protein expression, IL-23p19 mRNA could be detected by RT-PCR in RA SFMC. IL-17 and $IL-1{\beta}$ could induce RA SFMC to produce the IL-23p19. The effects of IL-17 were much stronger than $IL-1{\beta}$ or TNF-${\alpha}$. These responses were observed in a doseresponsive manner. In addition, IL-17 or $IL-1{\beta}$ neutralizing antibody down-regulated the expression of IL-23p19 induced by LPS in RA-SFMC. Our results demonstrate that IL-23p19 is overexpressed in RA synovium and IL-17 and $IL-1{\beta}$ appears to upregulate the expression of IL-23p19 in RA-SFMC.

파킨스병 유전인자인 LRRK2와 상호작용하는 methionyl-tRNA synthetase (Methionyl-tRNA-synthetase is a Novel Interacting Protein of LRRK2)

  • 김혜정;호동환;손일홍;설원기
    • 생명과학회지
    • /
    • 제28권2호
    • /
    • pp.170-175
    • /
    • 2018
  • 파킨슨병은 두번째로 많이 발병하는 퇴행성 신경질환이며 약 5-10%는 유전된다. Leucine-rich repeat kinase 2(LRRK2)는 그 돌연변이의 일부가 파킨슨병을 일으키는 유전자이다. LRRK2에는 인산화효소와 GTPase 기능이 있는 도메인과 함께 단백질 상호작용에 관여하는 Leucine-rich repeat (LRR), WD40 도메인이 존재하여, LRRK2와 상호작용하는 단백질이 파킨슨병 발병에 중요한 역할을 함을 암시한다. 우리는 이러한 LRRK2와 상호작용하는 단백질을 규명하여 그 단백질의 세포내 기능을 통해 역으로 LRRK2의 기능을 밝히고자 하였다. NIH3T3 세포 용해물을 LRRK2 항체와 IgG로 각각 면역침강하여 LRRK2 항체 침강반응에서만 특이적으로 나타나는 단백질 밴드를 질량 분석한 결과, methionyl-tRNA synthetase (MRS)로 나타났다. LRRK2와 MRS의 상호작용은 면역침강반응과 GST-pull down assay를 통해 확인됐다. 병을 유발하는, LRRK2의 돌연변이인 G2019S가 인산화효소 활성을 증가시키므로 LRRK2가 MRS를 인산화하는 지를 조사한 결과, LRRK2재조합단백질은 MRS 단백질을 인산화 하지 않았다. 또한 이들 두 단백질의 각각의 양 증가가 상대 단백질의 양 증가, 즉 안정성에 영향을 미치는 지를 조사하였으나 안정성의 변화를 관찰하지 못하였다. 결론적으로, MRS는 LRRK2와 상호작용을 하지만 LRRK2 인산화효소의 기질은 아니다.

Preparation and Characterization of Anti-GP73 Monoclonal Antibodies and Development of Double-antibody Sandwich ELISA

  • Li, Qi-Wen;Chen, Hong-Bing;Li, Zhi-Yang;Shen, Peng;Qu, Li-Li;Gong, Lai-Ling;Xu, Hong-Pan;Pang, Lu;Si, Jin
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권5호
    • /
    • pp.2043-2049
    • /
    • 2015
  • Background: Serum Golgi protein 73 (GP73) as a novel and potential marker for diagnosing hepatocellular carcinoma (HCC) have been found to be elevated in HCC patients and associated with clinical variables representing tumor growth and invasiveness. The aim of this study was to prepare a pair of monoclonal antibodys (mAbs) against GP73 and develop a newly designed double-antibody sandwich enzyme-linked immunosorbent assay (s-ELISA), which would be used in the detection of serum GP73 (sGP73) as well as in the diagnosis of HCC. Materials and Methods: Produced by prokaryotic expression, the purified recombinant GP73 (rGP73), produced by prokaryotic expression, was used to immunize the Balb/c mice. Two hybridoma cell lines against GP73 were obtained by fusing mouse Sp2/0 myeloma cells with spleen cells from the immunized mice. The titers of anti-GP73 mAb reached 1:243,000. Western blotting analysis and Immunohistochemistry staining revealed that anti-GP73 mAb could recognize GP73 protein. The double-antibody s-ELISA was successfully established and validated by 119 HCC and 103 normal serum samples. Results: showed that the detection limit of this method could reach 1.56 ng/ml, and sGP73 levels in HCC group (mean=190.6 ng/ml) were much higher than those of in healthy controls (mean=70.92 ng/ml). Conclusions: Results of our study not only showed that sGP73 levels of HCC patients were significantly higher than those of healthy controls, but also indicated that the laboratory homemade anti-GP73 mAbs could be the optimal tool used in evaluating sGP73 levels, which would provide a solid foundation for subsequent clinical applications.

Increased Cellular NAD+ Level through NQO1 Enzymatic Action Has Protective Effects on Bleomycin-Induced Lung Fibrosis in Mice

  • Oh, Gi-Su;Lee, Su-Bin;Karna, Anjani;Kim, Hyung-Jin;Shen, AiHua;Pandit, Arpana;Lee, SeungHoon;Yang, Sei-Hoon;So, Hong-Seob
    • Tuberculosis and Respiratory Diseases
    • /
    • 제79권4호
    • /
    • pp.257-266
    • /
    • 2016
  • Background: Idiopathic pulmonary fibrosis is a common interstitial lung disease; it is a chronic, progressive, and fatal lung disease of unknown etiology. Over the last two decades, knowledge about the underlying mechanisms of pulmonary fibrosis has improved markedly and facilitated the identification of potential targets for novel therapies. However, despite the large number of antifibrotic drugs being described in experimental pre-clinical studies, the translation of these findings into clinical practices has not been accomplished yet. NADH:quinone oxidoreductase 1 (NQO1) is a homodimeric enzyme that catalyzes the oxidation of NADH to $NAD^+$ by various quinones and thereby elevates the intracellular $NAD^+$ levels. In this study, we examined the effect of increase in cellular $NAD^+$ levels on bleomycin-induced lung fibrosis in mice. Methods: C57BL/6 mice were treated with intratracheal instillation of bleomycin. The mice were orally administered with ${\beta}$-lapachone from 3 days before exposure to bleomycin to 1-3 weeks after exposure to bleomycin. Bronchoalveolar lavage fluid (BALF) was collected for analyzing the infiltration of immune cells. In vitro, A549 cells were treated with transforming growth factor ${\beta}1$ (TGF-${\beta}1$) and ${\beta}$-lapachone to analyze the extracellular matrix (ECM) and epithelial-mesenchymal transition (EMT). Results: ${\beta}$-Lapachone strongly attenuated bleomycin-induced lung inflammation and fibrosis, characterized by histological staining, infiltrated immune cells in BALF, inflammatory cytokines, fibrotic score, and TGF-${\beta}1$, ${\alpha}$-smooth muscle actin accumulation. In addition, ${\beta}$-lapachone showed a protective role in TGF-${\beta}1$-induced ECM expression and EMT in A549 cells. Conclusion: Our results suggest that ${\beta}$-lapachone can protect against bleomycin-induced lung inflammation and fibrosis in mice and TGF-${\beta}1$-induced EMT in vitro, by elevating the $NAD^+$/NADH ratio through NQO1 activation.

유전자 패널 검사로 진단된 당원병 III형 증례 (A Case of Glycogen Storage Disease Type III Diagnosed by Gene Panel Sequencing)

  • 김성완;장주영;이장훈;손영배;장자현
    • 대한유전성대사질환학회지
    • /
    • 제20권1호
    • /
    • pp.24-28
    • /
    • 2020
  • 당원병 III형은 GDE 결핍으로 분해되지 않은 당원이 간 또는 근육에 축적되는 유전대사이상질환이다. AGL 유전자 변이에 의해 발생하고 높은 유전적 이질성을 가지고 있다. 당원병 III형의 임상증상은 간 비대, 성장 지연, 저혈당 등이 있다. 이러한 임상 증상은 다른 타입의 당원병의 증상과 비슷하여 임상적으로는 구분하기가 어렵다. 저자들은 간 비대 주소로 내원한 11개월 환아에서 유전자 패널 검사로 진단된 당원병 III형 증례를 보고하고자 한다. 간 조직검사결과 간세포에 글리코겐이 축적되어 있어 당원병을 의심하였으며, 당원병 아형의 감별 진단을 위해 유전자 패널 검사를 시행하였다. 그 결과, AGL 유전자에서 이전에 보고된 바 없는 c.311_312del와 c.3314+1G>A 변이가 이형접합체로 발견되어 당원병 III형으로 진단하였다. 진단 후 생옥수수 전분가루를 복용하는 식이요법 시작하였고, 생후 35개월인 현재까지 급·만성 합병증 없는 상태이다. 또한, 가족 검사를 통해 부모가 각각 보인자임을 확인하였고, 임신된 동생의 융모막 검사에서도 동일한 변이가 확인되어 출산 후 재검 및 조기 식이요법을 시행할 예정이다. 유전자 패널 검사법은 당원병과 같이 임상적으로 구분이 어려우며 높은 유전적 이질성을 가진 질환의 감별 진단 시 시간과 비용을 아낄 수 있어 유용하다. 또한 정확한 분자 유전학적 진단은 환아와 가족에게 질환에 대한 정확한 정보 및 치료 예방, 산전 유전상담을 제공하는 데 도움이 된다.

Brassinosteroid의 대사공학 (Metabolic Engineering of the Brassinosteroid Biosynthetic Pathways)

  • 이미옥;송기홍;이현경;정지윤;최빛나리;최성화
    • 한국식물생명공학회:학술대회논문집
    • /
    • 한국식물생명공학회 2002년도 추계학술대회
    • /
    • pp.69-75
    • /
    • 2002
  • Sterols play two major roles in plants: a bulk component in biological membranes and precursors of plant steroid hormones. Physiological effects of plant steroids, brassinosteroids (BRs), include cell elongation, cell division, stress tolerance, and senescence acceleration. Arabidopsis mutants that carry genetic defects in BR biosynthesis or its signaling display characteristic phenotypes, such as short robust inflorescences, dark-green round leaves, and sterility. Currently there are more than 100 dwarf mutants representing 7 genetic loci in Arabidopsis. Mutants of 6 loci, dwf1/dim1/cbb1, cpd/dwf3, dwf4, dwf5, det2/dwf6, dwf7 are rescued by exogenous application of BRs, whereas bri1/dwf2 shares phenotypes with the above 6 loci but are resistant to BRs. These suggest that the 6 loci are defective in BR biosynthesis, and the one locus is in BR signaling. Biochemical analyses, such as intermediate feeding tests, examining the levels of endogenous BR, and molecular cloning of the genes revealed that dwf7, dwf5, and dwf1 are defective in the three consecutive steps of sterol biosynthesis, from episterol to campesterol via 5-dehydroepisterol. Similarly, det2/dwf6, dwf4, and cpd/dwf3 were shown to be blocked in $D^4$ reduction, 22a-hydroxylation, and 23 a-hydroxylation, respectively. A signaling mutant bri1/dwf2 carries mutations in a Leucine-rich repeat receptor kinase. Interestingly, the bri1 mutant was shown to accumulate significant amount of BRs, suggesting that signaling and biosynthesis are dynamically coupled in Arabidopsis. Thus It is likely that transgenic plants over-expressing the rate-limiting step enzyme DWF4 as well as blocking its use by BRI1 could dramatically increase the biosynthetic yield of BRs. When applied industrially, BRs will boost new sector of plant biotechnology because of its potential use as a precursor of human steroid hormones, a novel lead compound for cholesterol-lowering effects, and a various application in plant protection.

  • PDF